NLS Pharmaceutics (NLSP) Competitors $1.95 -0.10 (-4.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.94 0.00 (-0.26%) As of 02/21/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NLSP vs. QTTB, BIVI, PLUR, SNYR, BFRG, IXHL, RLYB, PMN, CVM, and MRNSShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Q32 Bio (QTTB), BioVie (BIVI), Pluri (PLUR), Synergy CHC Corp. (Uplisting) (SNYR), Bullfrog AI (BFRG), Incannex Healthcare (IXHL), Rallybio (RLYB), ProMIS Neurosciences (PMN), CEL-SCI (CVM), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Q32 Bio BioVie Pluri Synergy CHC Corp. (Uplisting) Bullfrog AI Incannex Healthcare Rallybio ProMIS Neurosciences CEL-SCI Marinus Pharmaceuticals NLS Pharmaceutics (NASDAQ:NLSP) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations. Do insiders & institutionals have more ownership in NLSP or QTTB? 31.3% of Q32 Bio shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 16.1% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer NLSP or QTTB? In the previous week, Q32 Bio's average media sentiment score of 0.79 beat NLS Pharmaceutics' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media. Company Overall Sentiment NLS Pharmaceutics Neutral Q32 Bio Positive Does the MarketBeat Community believe in NLSP or QTTB? Q32 Bio received 4 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 66.67% of users gave Q32 Bio an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Q32 BioOutperform Votes1266.67% Underperform Votes633.33% Do analysts recommend NLSP or QTTB? Q32 Bio has a consensus target price of $24.86, suggesting a potential upside of 867.20%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility & risk, NLSP or QTTB? NLS Pharmaceutics has a beta of -0.35, meaning that its share price is 135% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.32, meaning that its share price is 132% less volatile than the S&P 500. Which has stronger earnings & valuation, NLSP or QTTB? NLS Pharmaceutics has higher earnings, but lower revenue than Q32 Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$12.17MN/AN/AQ32 Bio$1.16M26.99-$112.96M-$14.25-0.18 Is NLSP or QTTB more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Q32 Bio N/A -146.18%-54.49% SummaryQ32 Bio beats NLS Pharmaceutics on 9 of the 13 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.38M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / BookN/A6.717.644.62Net Income-$12.17M$138.33M$3.18B$245.85M7 Day Performance-13.72%-2.61%-1.99%-2.68%1 Month Performance3.17%-2.32%-0.42%-2.19%1 Year Performance375.61%-5.31%16.51%12.84% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.95-4.9%N/A+364.1%$7.38MN/A0.006Gap UpQTTBQ32 Bio2.9876 of 5 stars$2.67-0.4%$24.86+831.0%N/A$32.52M$1.16M-0.1939BIVIBioVie1.6241 of 5 stars$1.83+3.4%$3.00+63.9%+24.4%$32.52MN/A-0.1610PLURPluri0.2095 of 5 stars$4.62+3.1%N/A-30.3%$32.33M$678,000.00-0.77150SNYRSynergy CHC Corp. (Uplisting)N/A$3.70+5.7%$10.00+170.3%N/A$32.19MN/A0.0040Gap UpBFRGBullfrog AI0.2526 of 5 stars$3.65-7.8%N/A-32.1%$31.79M$60,000.00-4.294High Trading VolumeIXHLIncannex Healthcare0.5526 of 5 stars$1.78-1.0%N/A-74.4%$31.41M$86,000.00-1.283Earnings ReportRLYBRallybio2.4536 of 5 stars$0.75-4.0%$9.75+1,194.0%-58.1%$31.26M$598,000.00-0.4740PMNProMIS Neurosciences0.3518 of 5 stars$0.95-0.7%N/A-62.4%$31.06MN/A-9.505News CoverageCVMCEL-SCIN/A$0.42+2.9%N/A-81.5%$30.90MN/A-0.8243News CoverageMRNSMarinus Pharmaceuticals4.2119 of 5 stars$0.55-0.2%$4.79+771.6%-94.4%$30.32M$30.99M-0.22110Analyst Forecast Related Companies and Tools Related Companies Q32 Bio Alternatives BioVie Alternatives Pluri Alternatives Synergy CHC Corp. (Uplisting) Alternatives Bullfrog AI Alternatives Incannex Healthcare Alternatives Rallybio Alternatives ProMIS Neurosciences Alternatives CEL-SCI Alternatives Marinus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLSP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
